BPC-157 Half-Life and Pharmacokinetics
A neutral research overview of BPC-157 pharmacokinetics, including pre-clinical plasma half-life data, limited human data, and its Australian regulatory status.
What is the half-life of BPC-157?
Published pharmacokinetic data for BPC-157 comes almost entirely from pre-clinical animal studies. One rat and dog study reported a plasma elimination half-life of roughly 15 minutes after intravenous administration, with values under 30 minutes across the routes tested. No validated human pharmacokinetic half-life has been published.
It is important to read that figure in context. A half-life describes how quickly a compound's concentration in plasma falls by half in the species studied. The approximately 15 minute value was measured in laboratory animals, not people, so it cannot be transferred directly to any other context. The sections below summarise what the available research literature reports and, just as importantly, where it is silent.
What BPC-157 is as a molecule
BPC-157 is a synthetic pentadecapeptide, meaning it is a chain of 15 amino acids produced by chemical synthesis. In the research literature it is described as a partial sequence related to a protein identified in gastric juice, which is why older papers often refer to it as a body-protective compound fragment.
The commonly cited amino-acid sequence is GEPPPGKPADDAGLV, and its reported molecular weight is approximately 1419 daltons. These characteristics place it among the smaller research peptides, well below the size of most therapeutic proteins. For a broader profile of the compound as a research material, see the linked overview article.
- Class: synthetic pentadecapeptide (15 amino-acid residues)
- Reported sequence: GEPPPGKPADDAGLV
- Reported molecular weight: approximately 1419 daltons
- Origin: a sequence related to a protein found in gastric juice, prepared synthetically for laboratory research
Understanding pharmacokinetics terminology
Pharmacokinetics is the study of what happens to a compound inside a biological system over time. Researchers typically describe four broad processes, often shortened to ADME: absorption, distribution, metabolism and excretion. Half-life is one output of these processes and is usually reported alongside other measured parameters.
When a study measures pharmacokinetics, it is quantifying concentrations in plasma or tissue at set time points after administration in a research model. From those measurements, scientists calculate values such as peak concentration, the time to reach that peak, total exposure over time, bioavailability and elimination half-life. These are descriptive measurements of a model system, not statements about any effect in a person.
- Absorption: how the compound enters circulation in the model studied
- Distribution: how it spreads into tissues
- Metabolism: how it is chemically broken down
- Excretion: how it and its by-products leave the body
- Half-life: the time for plasma concentration to fall by half in that model
What the pre-clinical pharmacokinetic literature reports
The most frequently cited pharmacokinetic work on BPC-157 is a study in rats and dogs that tracked the compound after intravenous and intramuscular administration using labelled material. That study described approximately linear pharmacokinetics across the doses examined, which simply means exposure scaled in proportion to the amount given within the tested range.
Reported observations from that pre-clinical work included a short plasma elimination half-life, rapid attainment of peak plasma levels after intramuscular administration, and incomplete absolute bioavailability by that route in rats. The study also described urine and bile as the main excretory routes for the labelled material. All of these are animal-model findings.
- Elimination half-life reported at roughly 15 minutes after intravenous dosing in rats, under 30 minutes across tested routes
- Peak plasma levels reached quickly after intramuscular administration in the animal models
- Absolute intramuscular bioavailability reported in the region of 14 to 19 per cent in rats
- Urine and bile described as the main excretory pathways for labelled material
- Pharmacokinetics described as approximately dose-proportional within the tested range
Stability in gastric juice versus plasma half-life
A point of frequent confusion is the difference between stability in gastric juice and half-life in plasma. Much of the early research literature describes BPC-157 as relatively stable in human gastric juice in laboratory conditions, with some papers reporting persistence beyond a 24 hour window in that specific environment.
Stability in a test tube of gastric fluid is a separate measurement from how long a compound circulates in plasma once it has entered the bloodstream of a living animal. The two numbers answer different questions and should not be merged. Gastric-juice stability is often discussed in connection with how research peptides are handled and stored, a topic covered in the storage guide below.
The gap in human data
There is no robust, published human pharmacokinetic dataset for BPC-157. The compound has not progressed through the large, controlled human trials that would normally generate validated human half-life, clearance and exposure values. Review articles examining BPC-157 repeatedly note that human clinical data is limited and that most evidence remains pre-clinical.
This matters for anyone reading pharmacokinetic figures online. A precise human half-life stated with confidence should be treated with caution, because the published record does not currently support one. Where numbers exist, they are overwhelmingly derived from rodent and canine models. Comparing BPC-157 with how other peptides are characterised can help illustrate how different the data picture can be from one compound to another.
Regulatory and anti-doping status in context
In Australia, BPC-157 is not an approved therapeutic good. It is not registered on the Australian Register of Therapeutic Goods, and it is handled as a research-use-only laboratory compound rather than an approved medicine. Its legal and regulatory position is discussed in more detail in the dedicated status article.
In the anti-doping context, the World Anti-Doping Agency added BPC-157 to its Prohibited List with effect from 1 January 2022. It was listed as a named example under category S0, which covers non-approved substances that have no current approval for human therapeutic use by any government health authority. This is a regulatory classification and is noted here purely for completeness, not as any form of guidance.
How to read pharmacokinetic figures responsibly
Pharmacokinetic numbers are species-specific, route-specific and method-specific. A half-life measured in rats after intravenous administration tells you about that experiment, not about outcomes in any other species or by any other route. The analytical method used to detect the compound also shapes the result, which is why assay quality and compound purity are relevant background context.
When reviewing any pharmacokinetic claim for a research peptide, it helps to ask which species was studied, which route was used, how concentrations were measured and whether the data is pre-clinical or human. For BPC-157, the honest summary is that the published pharmacokinetic picture is short on human data and rests largely on a small number of animal studies.
Frequently asked questions
What is BPC-157 half-life?
Published data is limited and almost entirely pre-clinical. One rat and dog study reported a plasma elimination half-life of roughly 15 minutes after intravenous dosing, under 30 minutes across tested routes. No validated human half-life has been published.
Is there human pharmacokinetic data for BPC-157?
No robust human pharmacokinetic dataset has been published. Review articles note that human clinical data is very limited and that most pharmacokinetic evidence comes from rodent and canine models rather than controlled human studies.
How is BPC-157 pharmacokinetics measured?
In pre-clinical studies, researchers administer the compound to animal models and measure plasma or tissue concentrations at set time points, often using labelled material. From those measurements they calculate parameters such as peak concentration, bioavailability and elimination half-life.
Why is BPC-157 described as stable in gastric juice?
Some early research literature reports that BPC-157 remains relatively stable in human gastric juice under laboratory conditions, in some cases beyond 24 hours. That is a separate measurement from plasma half-life and should not be confused with how long it circulates in blood.
Is BPC-157 banned by WADA?
Yes. The World Anti-Doping Agency added BPC-157 to its Prohibited List with effect from 1 January 2022, listing it as a named example under category S0, which covers non-approved substances.
Is BPC-157 legal in Australia?
BPC-157 is not registered on the Australian Register of Therapeutic Goods and is not an approved medicine in Australia. It is handled as a research-use-only laboratory compound. See the dedicated status article for more detail.
What is the molecular weight of BPC-157?
BPC-157 is a synthetic pentadecapeptide of 15 amino acids with the commonly cited sequence GEPPPGKPADDAGLV and a reported molecular weight of approximately 1419 daltons.
This article is general information for research buyers. All Pepology products are supplied strictly for laboratory research use only and are not for human or animal use. Every batch is independently tested by Novagen Laboratories and verifiable on a public register.